Many of the fundamental trends and issues we’ve spotted in the past several years – the degree of leverage the diagnostics industry can gain from the integration of companion diagnostics into pharma’s development planning, the regulation of laboratory-developed tests, and the infiltration of next-generation genome sequencing on just about every level of drug/diagnostics development, for example – coalecsed in 2015, much as they had started to do last year when we titled our year-in-review piece “More of the Same.” (See Also see "Diagnostics In 2014: More Of The Same" - In Vivo, 21 January, 2015..) This past year may be thought of as one of acceptance, or consolidation of thought. These matters are now well-trod turf. But much new territory was also claimed during the year, most notably in the areas of digital health, data acquisition and analytics.
Diagnostics In 2015: Past Trends Coalesce, New Roads Open
The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.
More from Business Strategy
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
More from In Vivo
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.